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Abstract
Background: Sulindac is an FDA-approved non-steroidal anti-inflammatory drug (NSAID) that affects prostaglandin
production by inhibiting cyclooxygenases (COX) 1 and 2. Sulindac has also been of interest for more than decade as a
chemopreventive for adenomatous colorectal polyps and colon cancer.
Principal Findings: Pretreatment of human colon and lung cancer cells with sulindac enhances killing by an oxidizing agent
such as tert-butyl hydroperoxide (TBHP) or hydrogen peroxide. This effect does not involve cyclooxygenase (COX)
inhibition. However, under the conditions used, there is a significant increase in reactive oxygen species (ROS) within the
cancer cells and a loss of mitochondrial membrane potential, suggesting that cell death is due to apoptosis, which was
confirmed by Tunel assay. In contrast, this enhanced killing was not observed with normal lung or colon cells.
Significance: These results indicate that normal and cancer cells handle oxidative stress in different ways and sulindac can
enhance this difference. The combination of sulindac and an oxidizing agent could have therapeutic value.
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Introduction
Sulindac was one of the early non-steroidal anti-inflammatory
drugs (NSAIDs), which affect prostaglandin production by
inhibiting cyclooxygenases (COX) 1 and 2 [1]. For more than a
decade, sulindac has also been of interest as a chemopreventive
treatment for adenomatous colorectal polyps and colon cancer [2–
5], especially in patients with familial adenomatous polyposis [6].
Sulindac has also been reported as a chemopreventive agent for
mouse urinary bladder cancer [7]. The anti-tumorigenic activity of
sulindac against colon cancer may involve both COX inhibition
[2] and activities that are independent of COX inhibition [8–11].
It has been reported that sulindac induces apoptosis of colon
cancer cells, [11,12], which appears to involve changes in gene
expression [12–18].
Sulindac is a pro-drug that must be converted to the active
COX-inhibitor, sulindac sulfide [19]. We have previously shown
that conversion of sulindac to sulindac sulfide can be catalyzed by
MsrA, a member of the methionine sulfoxide reductase (Msr)
family of enzymes [20]. The Msr system has been studied in detail
in recent years, after it was shown that MsrA may play a role in
aging and age related diseases [21–23]. The obvious function of
the Msr system is to reduce methionine sulfoxide (Met(o)) in
proteins back to methionine (Met) (reviewed in [23]), although it
also functions as part of a ROS scavenger system, in which the
Msr system permits Met residues in protein to function as catalytic
antioxidants [24]. Support for the scavenger role of MsrA has
come from recent studies with both PC-12 neuronal cells, in which
MsrA was overexpressed [25], and human lens cells, in which
MsrA expression was down regulated [26]. Thus, there is
considerable evidence to suggest that the Msr system plays an
important role in protecting cells against oxidative damage.
Since sulindac is a substrate for MsrA [20], it seemed reasonable
that the killing of cancer cells by sulindac might involve oxidative
stress. Additionally, we wanted to determine whether normal cells
and cancer cells responded in a similar way(s) after sulindac
treatment and oxidative stress. In a preliminary study, we showed
that treatment of a squamous cell cancer cell line with sulindac and
an oxidizing agent led to nearly a 500% increase in intracellular
ROS levels and significant cell death. In contrast, normal human
epidermal keratinocytes did not show an increase in ROS levels or
cell death. These results led to a limited clinical trial that showed
promising potential of using topical application of sulindac and
hydrogen peroxide for treatment of actinic keratoses [27].
In the present studies we extended these earlier results using
cancer cell lines derived from lung and colon tissue. We provide
further evidence that the enhanced killing observed with sulindac
and oxidative stress involves mitochondrial dysfunction leading to
cell death via apoptosis. These new data strengthen the potential
for specifically enhancing the therapeutic application of sulindac
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5804and its derivatives for cancer treatment by using them in
conjunction with a compound that produces reactive oxygen
species (ROS).
Results
Sulindac enhances the killing of tumor cells by oxidative
stress, but does not involve either COX inhibition or the
Msr system
Human lung and colon cancer cell lines were preincubated in
the presence or absence of sulindac for 48 hours. Excess sulindac
was removed by washing prior to the 2 hr incubation with TBHP
as described in the Materials and Methods. Sulindac was used at
500 mM final concentration since preliminary experiments using
sulindac at this concentration showed no significant effect on cell
viability for either of the cancer cell lines.
Each cancer cell line had a marked decrease in cell viability in
the presence of TBHP following pretreatment with 500 mM
sulindac (Figure 1A and 1B). Viability of lung cancer cells
pretreated with sulindac was reduced by greater than 80%
following incubation for 2 hr with 240 mM TBHP when
compared to control cells that were not pretreated with sulindac
(Figure 1A). Similar responses to TBHP were observed with
sulindac treated colon cancer cells (Figure 1B), although a higher
concentration of TBHP was required for significant killing of the
colon cancer cells. Sulindac also enhanced the killing of both
cancer cell lines when TBHP was replaced with hydrogen
peroxide, at concentrations between 1.0 mM and 6.0 mM
(Figure 2).
Figure 1. Effect of sulindac on the viability of cancer cells in response to oxidative stress. Lung cancer cells (A) or colon cancer cells (B)
were incubated in the presence (&) or absence (%) of 500 mM sulindac for 48 hr. Cells were then washed to remove the free sulindac prior to
incubation for 2 hr with the indicated concentration of TBHP and cell viability was measured using the MTS assay described in Materials & Methods.
Cell viability is expressed as % of control (cells not pretreated with sulindac or exposed to TBHP). Error bars are standard error of the mean (SEM)
expressed as a % of the mean value of four replicate samples from a representative experiment. Significance of the differences between cells treated
with and without sulindac, but exposed to the same concentration of TBHP: *p,0.01; ** p,0.001; *** p,0.0001.
doi:10.1371/journal.pone.0005804.g001
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cancer cells by sulindac and oxidative stress does not involve COX
inhibition. Two other NSAIDs, acetylsalicylic acid (aspirin) and
ibuprofen, at 500 mM, failed to increase the sensitivity of cancer
cells to oxidative stress (Figure 3A and 3B, respectively). As noted
above, sulindac is a pro-drug that must be converted to the active
COX-inhibitor, sulindac sulfide [19], primarily through the
activity of MsrA [20]. To determine whether the enhanced killing
of sulindac-treated cancer cells by TBHP involved reduction of
sulindac to sulindac sulfide, the active inhibitor of cyclooxygenases,
Figure 2. Effect of sulindac on the viability of cancer cells in response to hydrogen peroxide. Lung cancer cells (A) or colon cancer cells
(B) were incubated in the presence (&) or absence (%) of 500 mM sulindac for 48 hr. Cells were then washed to remove the free sulindac prior to
incubation for 2 hr with the indicated concentration of hydrogen peroxide. Cell viability was measured using the MTS assay described in Materials &
Methods. Cell viability is expressed as % of control (cells not pretreated with sulindac or exposed to hydrogen peroxide). Error bars are standard error
of the mean (SEM) expressed as a % of the mean value of four replicate samples from a representative experiment. Significance of the differences
between cells treated with and without sulindac, but exposed to the same concentration of hydrogen peroxide: *p,0.01; ** p,0.001; *** p,0.0001.
doi:10.1371/journal.pone.0005804.g002
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cells were incubated in the presence (&) or absence (%) of either 500 mM acetylsalicylic acid (A), 500 mM ibuprofen (B) or 250 mM sulindac sulfone (C)
for 48 hr. Cells were then washed to remove the free NSAID or sulindac sulfone prior to incubation for 2 hr with the indicated concentration of TBHP.
Cell viability was measured using the MTS assay described in Materials & Methods. Cell viability is expressed as % of control (cells not exposed to an
NSAID, sulindac sulfone, or TBHP). Error bars are standard error of the mean (SEM) expressed as a % of the mean value of four replicate samples from
a representative experiment. Significance of the differences between cells treated with and without sulindac sulfone, but exposed to the same
concentration of TBHP: *p,0.01; ** p,0.001; *** p,0.0001.
doi:10.1371/journal.pone.0005804.g003
Sulindac, Cancer and ROS
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sulfone, which is not a substrate for MsrA (unpublished data) or a
COX inhibitor[28].Because of increased toxicityofsulindacsulfone
a lower concentration (250 mM) was used for these experiments.
Pretreatment of lung cancer cells with 250 mM sulindac sulfone
(Figure 3C), followed by exposure to TBHP gave comparable results
to those seen using 500 mM sulindac (compare Figures 1A and 3C).
Similar results using sulindac sulfone were also obtained with the
colon cancer cells lines (data not shown). Thus, the collective data
indicate that the increased sensitivity of sulindac treated cancer cells
to oxidative stress, under the conditions used, does not involve either
the Msr system or COX inhibition.
Sulindac does not enhance the killing of normal cells
exposed to oxidative stress
It was important to determine whether the enhanced killing
effect of sulindac and sulindac sulfone on cancer cells in the
presence of TBHP (Figure 1) also occurred with normal, non-
immortalized cells. Figure 4 shows the effect of pretreating
normal lung cells with sulindac or sulindac sulfone on cell
viability after oxidative stress using TBHP. Incubation of normal
lung cells with 500 mM sulindac for 48 hr prior to exposure to
TBHP not only did not enhance killing, but sulindac provided
protection from oxidative stress caused by TBHP (Figure 4A).
The protective effect from oxidative stress on normal lung cells
was also observed when cells were pretreated with sulindac
sulfone (Figure 4B).
Similar experiments were performed using the normal colon
cells. There was no effect on cell viability in the presence of TBHP
when the normal colon cells were pretreated with either 500 mM
sulindac or 250 mM sulindac sulfone (data not shown). Thus,
neither normal lung nor normal colon cells showed enhanced
killing by TBHP following treatment with sulindac or sulindac
sulfone, as was observed with the two cancer cell lines.
Figure 4. Sulindac and sulindac sulfone protect normal lung cells against oxidative stress. Normal lung cells were incubated for 48 hr in
(A) the presence (&) or absence (%) of 500 mM sulindac or (B) the presence (&) or absence (%) of 250 mM sulindac. See Materials and Methods and
legend to Figure 1 for further details. Significance of the differences between cells treated with and without sulindac or sulindac sulfone, but exposed
to the same concentration of TBHP: *p,0.01; ** p,0.001; *** p,0.0001.
doi:10.1371/journal.pone.0005804.g004
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elevated levels of ROS and loss of mitochondrial
membrane potential
Lung cancer cells were used to gain more information on the
mechanism of the enhanced killing effect of sulindac in the
presence of TBHP. To investigate whether the enhanced killing of
the cancer cells observed with sulindac and oxidative stress might
involve mitochondrial dysfunction, changes in the level of
intracellular ROS were determined. For these experiments lung
cancer cells were treated with sulindac for 48 hours, exposed to
TBHP and then the intracellular ROS level was visualized using a
fluorescent dye as described in the Materials and Methods. The
results are shown in Figure 5. Compared to untreated lung cancer
cells (Figure 5A), cells treated with sulindac alone (Figure 5B) or
TBHP alone (Figure 5C) showed a modest increase (53–58%) in
ROS levels based on appearance of green fluorescence. However,
lung cancer cells that were pretreated with 500 mM sulindac
followed by a 2 hr incubation with 80 mM TBHP (Figure 5D) had
a 400% increase in intracellular green fluorescence compared to
untreated cells (compare Figure 5A and 5D). These data clearly
show that pretreatment of the lung cancer cells with sulindac leads
to a large increase in intracellular ROS following exposure to
oxidative stress, supporting the results on skin cancer cells reported
recently [27].
To further explore the mechanism of killing cancer cells
exposed to oxidative stress after pretreatment with sulindac, we
investigated whether there is a concomitant loss of mitochondrial
membrane potential, which is known to initiate apoptotic cell
death. Effects on mitochondrial membrane potential were
evaluated using changes in the fluorescence of the JC-1 dye as
described in Materials and Methods. The results are shown in
Figure 6. The top panels show red fluorescent images and the
lower panels green fluorescent images. Loss of mitochondrial
membrane potential would result in decreased red fluorescence
and a corresponding increase in green fluorescence. Relative to
untreated cells (Figure 6A) or cells treated with only sulindac
(Figure 6B) or TBHP alone (Figure 6C), sulindac pretreatment of
lung cancer cells followed by oxidative stress (Figure 6D) resulted
in disruption of mitochondrial membrane potential as evidenced
by nearly a 20-fold increase in green fluorescence (see legend of
Figure 6 for additional details). In summary, pretreatment of the
lung cancer cells with sulindac followed by treatment with TBHP
leads to a marked increase in intracellular ROS and a significant
loss of mitochondrial membrane potential. These results indicated
that cell death was occurring via apoptosis, which was confirmed
by Tunel analysis (Supplementary Figure S1)
Discussion
Sulindac and its metabolites, such as sulindac sulfide and
sulindac sulfone, have been shown to have anti-cancer activity
[29]. Consistent with our previous study of skin cancer cells [27],
we have shown that the killing of lung and colon tumor cell lines
can be enhanced significantly if sulindac is combined with an
oxidant, such as TBHP or hydrogen peroxide. We also have
shown that sulindac pretreatment can enhance the killing of skin
cancer cells caused by arsenic trioxide (data not shown), which kills
cancer cells by generating intracellular ROS, as reported
elsewhere for lung cancer cells [30]. It seems reasonable that
sulindac may enhance the efficacy of any anticancer drug where
the mechanism of action involves oxidative damage. The
successful application of a multiple drug therapy has been recently
reported for a clinical trial involving almost 300 patients at risk for
recurrence of colorectal adenomas who were treated with a
combination of sulindac and difluoromethylornithine, an inhibitor
of polyamine synthesis [31].
It appears likely that the mechanism of the selective killing of
cancer cells seen in these studies involves mitochondrial dysfunc-
tion, possibly as a result of increased ROS production. While
treatment of cancer cells with sulindac or TBHP individually leads
to a modest increase in the level of ROS (Figure 5B and [27,32]),
there is a dramatic increase in the intracellular levels of ROS in
cells pretreated with sulindac and then exposed to TBHP
(Figure 5D). In addition, there is a significant disruption of
mitochondrial membrane potential under the same experimental
Figure 5. Intracellular ROS levels in lung cancer cells pretreated with sulindac followed by oxidative stress. The panels show
intracellular ROS fluorescence. (A) untreated cells; (B) cells treated with only sulindac; (C) cells treated with only TBHP; (D) cells treated with both
sulindac and TBHP. The incubation conditions are described in Figure 1. The cells were prepared for fluorescence microscopy and the green
fluorescence signal was quantified as described in Materials and Methods. Fluorescence levels are the average of two independent experiments and
were adjusted for the percentage of viable cells. The SEM was less than 10% for each sample. The increase in fluorescence compared to control cells
in panel A are: B, 53%; C, 57%; D, 401%.
doi:10.1371/journal.pone.0005804.g005
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cancer cells exposed to oxidative stress. The anticancer effect of
sulindac alone has been reported to involve apoptotic death [33].
The results with sulindac sulfone and other NSAIDs indicate that
the effect of sulindac in our system does not involve COX
inhibition or the Msr system.
The present results indicate a fundamental difference in the way
normal and cancer cells respond to oxidative stress. Sulindac and
its metabolites can accentuate this difference, which leads to
enhanced killing of cancer cells, but not normal cells, by oxidative
stress. It is well established that cancer and normal cells differ in
their oxidative metabolism and that cancer cells have a higher rate
of glycolysis than normal cells, a phenomenon first described by
Warburg [34]. There also is compelling evidence that cancer cells
are typically under greater oxidative stress compared to normal
cells [35]. A difference between normal and cancer cells to
oxidative stress that has been reported is the cytotoxicity caused by
glucose deprivation. Studies by Spitz and coworkers [36] have
clearly shown that this effect is mediated by mitochondrial ROS
production.
The results described provide further evidence that a combina-
tion of sulindac and an oxidizing agent might have clinical
therapeutic value in treating a variety of cancers. In a previous
preliminary study we reported that the results of a limited proof of
concept human clinical trial using sulindac (1–5%) and hydrogen
peroxide (25%) gels applied daily for three weeks on actinic
keratoses (AK) involving the upper extremities [27]. Upon
completion, all ten treated AKs showed a reduction in size as
shown by clinical photography with five exhibiting complete
disappearance of the precancerous cells after skin biopsy. These
preliminary results warrant more extensive clinical trials.
Materials and Methods
Materials
Sulindac, acetylsalicylic acid (aspirin), (S)-(+)-ibuprofen, and tert
butyl-hydroperoxide (TBHP) were obtained from Sigma (St.
Louis, MO). Sulindac sulfone was synthesized by Custom
Synthesis Inc. (Boca Raton, FL). All tissue culture media including
fetal bovine serum and other supplements were purchased from
American Type Culture Collection (ATCC; Rockville, MD).
Cell Culture
A colon cancer cell line (RKO), a lung cancer cell line (A549),
and fibroblast cell lines derived from normal human colon tissue
(CCD-18Co) and normal human lung (MRC-5) were obtained
from ATCC (Rockville, MD). All cell lines were maintained in the
recommended culture medium. The normal cell lines were not
immortalized and early passage cells were used for the experiments
reported here. Cell lines were determined to be free of
mycoplasma using the VenorGeMH Mycoplasma Detection Kit
(Sigma-Aldrich), which is a highly sensitive PCR-based assay.
Cell Viability Assay
Unless otherwise indicated, the cells were pretreated with
sulindac, sulindac sulfone or another NSAID for 48 hr prior to
exposure to TBHP for 2 hr. Cell suspensions (,100,000 cells)
containing the indicated supplement were plated in 96 well
microtiter plates using 100 ml of the indicated cell suspension. The
plates were incubated for 48 hr at 37uC in a 5% CO2 incubator.
The culture medium was then removed and the cells washed once
with fresh culture medium with serum. After removal of the wash
solution, fresh culture medium with serum that contained the
indicated final concentration of TBHP or hydrogen peroxide was
added to the cells, and the cells were incubated an additional
2 hours. Similar results were obtained when sulindac was included
during the 2 hr treatment with the oxidizing agent.
Cell viability was determined by the CellTiter 96 Aqueous One
Cell Proliferation Assay (Promega; Madison, WI) according to the
manufacture’s instructions. The assay utilizes a novel tetrazolium
compound that metabolically active cells convert to a water-
soluble formazan by the action of cellular dehydrogenases, which
is measured by absorbance at 490 nm using a colorimetric
microtiter plate reader (SpectraMax Plus
384; Molecular Devices).
Figure 6. Mitochondrial membrane potential as measured by JC-1 distribution in lung cancer cells. Upper panels show red fluorescence
images while lower panels show green fluorescence images. Loss of mitochondrial membrane potential was detected by a decrease of red
fluorescence with a concomitant increase of green florescence. The experimental design is described in the legends of Figure 1. (A) untreated cells;
(B) cells treated with only sulindac; (C) cells treated with only TBHP; (D) cells treated with both sulindac and TBHP. The cells were prepared for
fluorescence microscopy and the fluorescence signal was quantified as described in Materials and Methods. Results are an average of three
independent experiments. SEM was less than 10% for each sample. Quantitative analysis of green fluorescence is expressed as follows in arbitrary
units: panel A –1.39; panel B –1.23; panel C –1.29; panel D –25.3.
doi:10.1371/journal.pone.0005804.g006
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been reported that some anticancer drugs can cause changes in
absorbance in MTS-based assays for cell viability in the absence of
cells [37]. Control experiments using sulindac alone, TBHP alone
or combinations of sulindac and TBHP over the concentration
range used in the reported experiments showed no effect of either
compound alone or in combination on absorbance.
Intracellular ROS Assay
Intracellular ROS levels were determined by using the Reactive
Oxygen Species (ROS) Detection Reagents from Molecular
Probes (Eugene, OR) as described elsewhere [38]. Elevated levels
of ROS result in increased green fluorescence, which was
visualized by fluorescence microscopy.
JC-1 assay to measure mitochondrial membrane
potential
Loss of mitochondrial membrane potential was determined
using the JC-1 dye from Molecular Probes (Eugene, OR). Loss of
mitochondrial membrane potential leads to increased green
fluorescence in the cytosol and a corresponding decrease in
mitochondrial red fluorescence. Thus, changes in mitochondrial
membrane potential were determined by following the red to
green staining shift using an FITC filter (Zeiss inverted
microscope-Axiovert 40 CFL). Quantitation of the fluorescence
signals used both standard densitometric methods and a Photo-
shop (Adobe Systems, San Jose, CA) based image analysis [39].
TUNEL Assay to demonstrate apoptosis
Apoptotic cells were detected using the Deadend (Promega)
colorimetric TUNEL assay that end labels fragmented DNA. Cells
were fixed with 4% formaldehyde before being permeabilized with
0.2% triton-X-100. Cells were then washed with PBS prior to
incubation with recombinant terminal deoxynucleotidyl transfer-
ase(TdT) and biotinylated nucleotides for 1 h at 37uC, which
incorporates the biotinylated nucleotides at 39 ends of fragmented
DNA. Cells were washed with PBS and then incubated with
horseradish peroxidase-streptavidin (HRP-Streptavidin) at room
temperature for 30 min. HRP-streptavidin labeled cells were
detected by hydrogen peroxide and diaminobenzidine (DAB).
Apoptotic cells are visualized by dark brown nuclear staining.
Statistical analysis
Results of cell viability experiments are expressed as the mean of
four replicates of a representative experiment. The error bars
indicate the standard error of the mean (SEM). Means were
compared using standard t-tests and the P-values are indicated in
the figure legends. P values,0.05 were considered statistically
significant. Quantitation of the fluorescence signals used both
standard densitometric methods and a Photoshop (Adobe Systems,
San Jose, CA) based image analysis [39].
Supporting Information
Figure S1 Cell Death due to Apoptosis. A TUNEL assay was
used to detect apoptosis of lung cancer cells. (A) untreated cells; (B)
cells treated with only 500 mM sulindac; (C) cells treated with only
180 mM TBHP; (D) cells treated with both 500 mM sulindac and
180 mM TBHP. Increased levels of apoptosis are indicated by
enhanced formation of brown coloration. The experimental design
is described in the legends of Figure 1 in the manuscript.
Additional details of the TUNEL assay are provided in the
Materials and Methods.
Found at: doi:10.1371/journal.pone.0005804.s001 (0.22 MB TIF)
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